JAK2 and myeloproliferative disorder: Several JAK2-V617F-positive cell lines have been derived from patients with post-MPN sAML, including PVTL-1 and PVTL-2 as we established previously, to be used in various studies on JAK2-V617F-mediated signaling and leukemogenesis [5,6,7].